Recruiting

Cerebral Blood Flow and Vascular Function in Women with Gestational Diabetes History

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

Intradermal Microdialysis

+ Brain Blood Flow Tests

+ Local Heating

DrugOther
Who is being recruted

Urogenital Diseases+6

+ Diabetes Mellitus

+ Endocrine System Diseases

From 18 to 50 Years
See all eligibility criteria
How is the trial designed

Basic Science Study

Phase 1
Interventional
Study Start: August 2025
See protocol details

Summary

Principal SponsorAnna Stanhewicz, PhD
Study ContactAnna Reid-Stanhewicz, PHD
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: August 22, 2025

Actual date on which the first participant was enrolled.

Gestational Diabetes Mellitus (GDM) affects about 14% of pregnancies globally, and its impact can extend well beyond the pregnancy period. Women who have had GDM are at a higher risk of developing blood vessel-related brain diseases and dementia compared to those with uncomplicated pregnancies. This study aims to understand how GDM affects blood flow in the brain and the function of brain blood vessels in healthy women who have previously had GDM or an uncomplicated pregnancy. By gaining insights into these effects, the study hopes to address the lack of information on how GDM influences brain health after pregnancy and ultimately improve future care and prevention strategies. Participants in this study will undergo non-invasive ultrasound tests to measure blood flow in the brain. The study will also evaluate how brain blood vessels respond to increased carbon dioxide levels, similar to what occurs during a breath hold. Researchers will compare these brain blood flow results with skin blood vessel function by using a gentle technique on small areas of the forearm. This involves a minor procedure to deliver medications locally under the skin. Blood samples will also be taken to assess overall health and explore factors affecting blood vessel function. This comprehensive approach helps identify potential links between GDM and brain vessel health, aiming to improve understanding of its long-term effects.

Official TitleThe Impact of Gestational Diabetes Mellitus on Cerebral Blood Flow and Cerebrovascular Function After Pregnancy
NCT06911372
Principal SponsorAnna Stanhewicz, PhD
Study ContactAnna Reid-Stanhewicz, PHD
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

84 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Basic Science Study

Basic science studies help researchers understand how the body works or how a disease develops. They don't test treatments, but they build the foundation for future therapies.



Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Female

Biological sex of participants that are eligible to enroll.

From 18 to 50 Years

Range of ages for which participants are eligible to join.

Healthy volunteers allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Urogenital DiseasesDiabetes MellitusEndocrine System DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsMetabolic DiseasesNutritional and Metabolic DiseasesPregnancy ComplicationsDiabetes, GestationalGlucose Metabolism Disorders

Criteria

INCLUSION CRITERIA: * Post-partum women * 18 years or older * Delivered within 5 years from the study visit * History of gestational diabetes diagnosed by an obstetrician and confirmed according to the American College of Obstetricians and Gynecologists criteria for gestational diabetes OR history of uncomplicated pregnancy (defined as no history of gestational diabetes, hypertensive pregnancy, or other gestational disorder). EXCLUSION CRITERIA: We exclude participants from both groups for: * Skin diseases * Current tobacco use * Diagnosed or suspected hepatic or metabolic disease including diabetes * Diagnosed with depression or other mood-related disorders, asthma, chronic obstructive pulmonary disease, cystic fibrosis, or pulmonary fibrosis * Use of prescribed NSAIDs, statins or other cholesterol-lowering medication, antihypertensive medication, carbonic anhydrase inhibitors, corticosteroids, thyroid medications, antidepressants or mood stabilizers, diuretics, phenothiazines, or benzodiazepines * History of preeclampsia or gestational hypertension, * History or family history of panic disorder, * Currently pregnant * Body mass index \<18.5 kg/m2, * Allergy to materials used during the experiment (e.g. latex), known allergies to study drugs. * History of heavy alcohol use/binge drinking, * Have planned procedures with radiological contrast, * Have a major dental procedure/surgery coming up, such as a dental extraction * Anatomy of the middle cerebral artery or internal carotid artery that prevents adequate ultrasonography and/or and data collection

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

One single intervention group is designated in this study

This study does not include a placebo group 

Treatment Groups

Group I

Experimental
All women will complete the same protocol, regardless of pregnancy history.

Study Objectives

Primary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Recruiting

Iowa Bioscience Innovation Facility

Iowa City, United StatesOpen Iowa Bioscience Innovation Facility in Google Maps
Recruiting
One Study Center